Researchers reported phase II results for a combination intended to treat cancers of unknown primary (CUP) with a regimen that pairs an anti-PD-1 immune checkpoint inhibitor with nab-paclitaxel. The study is framed as a second-line approach and focuses on clinical signals from patients with CUP who lack an established tissue origin. The work led by Zhang and co-authors adds to a small set of CUP-directed strategies that attempt to convert immunogenicity and chemotherapy exposure into measurable response rates. Details in the provided report emphasize the trial structure and therapy components but do not include full efficacy metrics, leaving the clinical impact tied to forthcoming publication-level outcomes.